{"id":"atomoxetine-and-oros-methylphenidate","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Elevated blood pressure"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atomoxetine selectively inhibits the norepinephrine transporter, increasing norepinephrine availability in the prefrontal cortex and improving attention and executive function. OROS methylphenidate is a long-acting formulation that blocks dopamine and norepinephrine reuptake, providing sustained symptom control throughout the day. The combination targets complementary pathways to enhance attention and reduce impulsivity and hyperactivity.","oneSentence":"This is a combination of two norepinephrine-enhancing medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and OROS methylphenidate (an extended-release stimulant that increases dopamine and norepinephrine).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:03.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT00916786","phase":"","title":"Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":240},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT02352051","phase":"PHASE4","title":"Effects of Atx and Oros-mph on Executive Functions","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-02","conditions":"Executive Dysfunction","enrollment":43},{"nctId":"NCT00880217","phase":"PHASE2","title":"A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":430},{"nctId":"NCT01127646","phase":"PHASE4","title":"A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00585910","phase":"PHASE4","title":"Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-01","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":94},{"nctId":"NCT01065259","phase":"PHASE4","title":"Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":262},{"nctId":"NCT01130467","phase":"","title":"Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-09","conditions":"Attention Deficit Disorders With Hyperactivity, Attention Deficit Disorder, Hyperkinetic Syndrome","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Strattera, Concerta"],"phase":"marketed","status":"active","brandName":"Atomoxetine and OROS Methylphenidate","genericName":"Atomoxetine and OROS Methylphenidate","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two norepinephrine-enhancing medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and OROS methylphenidate (an extended-release stimulant that increases dopamine and norepinephrine). Used for Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}